COVID19: uncovering interindividual variability for tailoring appropriate therapeutic interventions
The severity of SARS-CoV2 infection, Covid19 disease, should account for the diversity of human individual immunoinflammatory responses. Serum immunological markers during Covid19 illness may lead to individualized therapeutics with better outcomes. Efficient treatment for Covid19 may require: 1) early disease detection, 2) combined drug therapy for 3) targeting the virus replication cycle, and 4) individualized drug treatment for specific immunoinflammatory human profile responses administered in a 5) timely manner. Covid19 is unlikely to be the last emergent human disease with fast pandemic potential. Gathering knowledge on the individual human host profiles of immunoinflammatory responses is an opportunity that could lead us to understand individual differences in response to infection at the individual and population level, paving the way to faster, more efficient strategies to tackle upcoming infectious diseases. This is a position paper based on an integrative non-exhaustive literature revision..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Medicina - 55(2022), 2 |
| Sprache: |
Portugiesisch |
|---|
| Beteiligte Personen: |
Maria Goreti Rosa Freitas [VerfasserIn] |
|---|
| Links: |
doaj.org [kostenfrei] |
|---|
| Themen: |
COVID19 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ034670874 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ034670874 | ||
| 003 | DE-627 | ||
| 005 | 20230307191805.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2022 xx |||||o 00| ||por c | ||
| 035 | |a (DE-627)DOAJ034670874 | ||
| 035 | |a (DE-599)DOAJ32f5e38b4bdf40be96211e857ce427d0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a por | ||
| 100 | 0 | |a Maria Goreti Rosa Freitas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID19: uncovering interindividual variability for tailoring appropriate therapeutic interventions |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The severity of SARS-CoV2 infection, Covid19 disease, should account for the diversity of human individual immunoinflammatory responses. Serum immunological markers during Covid19 illness may lead to individualized therapeutics with better outcomes. Efficient treatment for Covid19 may require: 1) early disease detection, 2) combined drug therapy for 3) targeting the virus replication cycle, and 4) individualized drug treatment for specific immunoinflammatory human profile responses administered in a 5) timely manner. Covid19 is unlikely to be the last emergent human disease with fast pandemic potential. Gathering knowledge on the individual human host profiles of immunoinflammatory responses is an opportunity that could lead us to understand individual differences in response to infection at the individual and population level, paving the way to faster, more efficient strategies to tackle upcoming infectious diseases. This is a position paper based on an integrative non-exhaustive literature revision. | ||
| 650 | 4 | |a COVID19 | |
| 650 | 4 | |a severe acute respiratory syndrome | |
| 650 | 4 | |a immunoinflammatory response | |
| 650 | 4 | |a iceberg model of disease | |
| 650 | 4 | |a treatment outcome | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Carolina Muruci-Cruz |e verfasserin |4 aut | |
| 700 | 0 | |a Luiz Fernando Dale |e verfasserin |4 aut | |
| 700 | 0 | |a Luis Eduardo da Cruz |e verfasserin |4 aut | |
| 700 | 0 | |a Jorge Kalil |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Medicina |d Universidade de São Paulo, 2020 |g 55(2022), 2 |w (DE-627)DOAJ078633532 |x 21767262 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2022 |g number:2 |
| 856 | 4 | 0 | |u https://doaj.org/article/32f5e38b4bdf40be96211e857ce427d0 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.revistas.usp.br/rmrp/article/view/180873 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0076-6046 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2176-7262 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2022 |e 2 | ||